Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672733 | 0.95 | ADORA2A (0.46) | ADORA2AADORA2BCHRM1GSK3BCD38 | |
| SCHEMBL23672727 | 0.87 | CHRM1 (0.44) | ADORA2ACHRM1PDE2APDE11AADORA1 | |
| SCHEMBL23672858 | 0.87 | CHRM1 (0.51) | ADORA2AADORA2BCHRM1METTL3PDE2A | |
| SCHEMBL23672569 | 0.87 | CHRM1 (0.44) | ADORA2ACHRM1PDE2APDE11AADORA1 | |
| SCHEMBL23672634 | 0.85 | CHRM1 (0.48) | ADORA2AADORA2BCHRM1PDE2APDE11A | |
| SCHEMBL23672767 | 0.84 | CHRM1 (0.49) | CHRM1PDE2APDE11ACD38 | |
| SCHEMBL23672774 | 0.84 | CHRM1 (0.49) | CHRM1PDE2APDE11ACD38 | |
| SCHEMBL23672848 | 0.83 | CD38 (0.41) | ADORA2AADORA2BCHRM1PDE2APDE11A | |
| SCHEMBL23672985 | 0.82 | CHRM1 (0.49) | ADORA2AADORA2BCHRM1 | |
| SCHEMBL23673026 | 0.80 | CHRM1 (0.49) | ADORA2AADORA2BCHRM1METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | claimed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | claimed |
| EP-3416639-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | ADORA2A 62/4885ADORA2B 228/4885CHRM1 1/4885 |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | ADORA2A 62/4885ADORA2B 228/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.